COMBAT 1: A Phase II Trial of Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma

Trial Profile

COMBAT 1: A Phase II Trial of Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Apr 2017

At a glance

  • Drugs Aldesleukin (Primary) ; Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms COMBAT-1
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Jan 2017 Time frame of primary end point has been changed fro 2 years to 3 years.
    • 18 Jan 2017 Status changed from active, no longer recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top